Filing Flows › IGC Pharma (IGC) › R&D spending
IGC Pharma (IGC) R&D spending by quarter
IGC Pharma's R&D spending was $1.0M in Q3 2026 (third quarter 2026), -27% from Q2 2026. Over the last 7 quarters it ranged from $851K (Q2 2025) to $1.6M (Q3 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $1.0M | -27% | -36% |
| Q2 2026 | $1.4M | +9% | +63% |
| Q1 2026 | $1.3M | -20% | +28% |
| Q3 2025 | $1.6M | +87% | — |
| Q2 2025 | $851K | -15% | — |
| Q1 2025 | $997K | +17% | — |
| Q4 2024 | $852K | — | — |
Q3 2026 at a glance
IGC Pharma, Q3 2026: revenue $328K (+72% year over year), operating margin -588.7%, net loss $2.0M, operating cash flow −$1.4M. The chart follows the revenue to costs, profit and cash.
Questions
What is IGC Pharma's R&D spending?
IGC Pharma's R&D spending was $1.0M in Q3 2026 (third quarter 2026), -27% from Q2 2026.
How has IGC Pharma's R&D spending changed?
Over the last 7 quarters it ranged from $851K (Q2 2025) to $1.6M (Q3 2025).